A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer
#ESMO26 #ESMOAmbassadors
👉 ORR: 18 vs 5.3%
👉 mPFS: 4.7 vs 2.6 mo
👉 mOS: 8.9 vs 9.4 mo
🧐Active drug, but no OS benefit in 2nd line, could be explored in 1L
@myESMO @ASCO
92 views · 4 likes · 4 reposts · 0 replies
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.orgSource: Arndt Vogel · x.com